JPS6365653B2 - - Google Patents
Info
- Publication number
- JPS6365653B2 JPS6365653B2 JP53104845A JP10484578A JPS6365653B2 JP S6365653 B2 JPS6365653 B2 JP S6365653B2 JP 53104845 A JP53104845 A JP 53104845A JP 10484578 A JP10484578 A JP 10484578A JP S6365653 B2 JPS6365653 B2 JP S6365653B2
- Authority
- JP
- Japan
- Prior art keywords
- lysozyme
- tumor
- group
- days
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010014251 Muramidase Proteins 0.000 claims description 79
- 102000016943 Muramidase Human genes 0.000 claims description 79
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 79
- 229960000274 lysozyme Drugs 0.000 claims description 79
- 239000004325 lysozyme Substances 0.000 claims description 79
- 235000010335 lysozyme Nutrition 0.000 claims description 79
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 42
- 201000011510 cancer Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 13
- 229960004397 cyclophosphamide Drugs 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229940034982 antineoplastic agent Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009876 antimalignant effect Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000002301 combined effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 5
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 235000014103 egg white Nutrition 0.000 description 5
- 210000000969 egg white Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 208000012657 Atopic disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- -1 and 2 days later Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000010550 lymph gland swelling Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10484578A JPS5533408A (en) | 1978-08-30 | 1978-08-30 | Immunity-increasing agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10484578A JPS5533408A (en) | 1978-08-30 | 1978-08-30 | Immunity-increasing agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5533408A JPS5533408A (en) | 1980-03-08 |
JPS6365653B2 true JPS6365653B2 (ko) | 1988-12-16 |
Family
ID=14391656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10484578A Granted JPS5533408A (en) | 1978-08-30 | 1978-08-30 | Immunity-increasing agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5533408A (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL173978B1 (pl) * | 1992-07-13 | 1998-05-29 | Nika Health Products Ltd | Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej |
US6183742B1 (en) | 1992-07-13 | 2001-02-06 | Nika Health Products, Limited | Applications of lysozyme dimer |
DZ1964A1 (fr) * | 1995-01-13 | 2002-10-15 | Nika Health Products Ltd | Nouvelle applications d'un dimère de lysozyme. |
US6123937A (en) * | 1997-03-14 | 2000-09-26 | Nika Health Products, Limited | Applications of lysozyme dimer |
CN1205917C (zh) * | 2002-06-05 | 2005-06-15 | 长春奇龙生物技术研究所 | 一种人溶菌酶系列化妆品及其制备方法 |
US20030235613A1 (en) * | 2002-06-19 | 2003-12-25 | Cts Chemical Industries Ltd. | Popping oral administration form |
ITMI20061950A1 (it) * | 2006-10-11 | 2008-04-12 | Therapicon Srl | Effetto antimetastatico in condizioni patologiche delle cellule umane |
-
1978
- 1978-08-30 JP JP10484578A patent/JPS5533408A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5533408A (en) | 1980-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4592041B2 (ja) | 生活の質を改善する新規食品の製造法および用途 | |
RU2159614C2 (ru) | Высушенные замораживанием композиции ондансетрона и способ лечения млекопитающих | |
ES2700278T3 (es) | Formulaciones para efectores de la unión estrecha | |
TW576743B (en) | Extended release formulations of erythromycin derivatives | |
US5631022A (en) | Picosulfate dosage form | |
BRPI0608853B1 (pt) | composições farmacêuticas e processo para a fabricação de microgrânulos de rifaximina gastrorresistentes | |
KR20040004638A (ko) | 의약 조성물 | |
RO121082B1 (ro) | Compoziţie farmaceutică, învelită cu un stratde acoperire enterosolubil | |
JPH10147517A (ja) | 高められた崩壊特性を有するフイルムコーテイングされた錠剤組成物 | |
JP3633936B2 (ja) | センナ剤形 | |
WO2008122190A1 (fr) | Composition comprenant de la l-carnitine ou ses dérivés et son utilisation | |
CN113613630A (zh) | 地匹福林口腔崩解片剂制剂 | |
JP2002525266A (ja) | 感染性潰瘍又は胃炎に対するタウロリジン及び/又はタウルルタム | |
JP2013537221A (ja) | 改良された経口標的化薬物送達システム | |
CN1878539B (zh) | 含苦味药物和pH敏感性聚合物的掩味的药物组合物 | |
JPS6365653B2 (ko) | ||
TW200526268A (en) | Injectable composition | |
JP2001518481A (ja) | 経口投与のためのセロトニン含有製剤及びその使用方法 | |
JPH09154535A (ja) | 納豆菌含有組成物 | |
JPS633850B2 (ko) | ||
CZ20032256A3 (en) | Medicinal compositions comprising diclofenac and ornoprostil | |
KR20230027226A (ko) | 화학요법-유발 설사를 치료하기 위한 방법 및 조성물 | |
RU2417087C2 (ru) | Комбинированная противотуберкулезная фармацевтическая композиция | |
RU2498803C1 (ru) | Противотуберкулезное лекарственное средство | |
JPH10511637A (ja) | ヒスタミンh▲下2▼−アンタゴニストの吸収を増強するためのグルコースのようなパラセルラー吸収エンハンサーの使用 |